Literature DB >> 20652638

Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma.

M Alberiche Ruano1, M Boronat Cortés, A Ojeda Pino, C Rodriguez Perez, M Gracía Nuñez, D Marrero Arencibia, F J Novoa Mogollón.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20652638     DOI： 10.1007/s11102-010-0237-4

Source DB:  PubMed          Journal:  Pituitary        ISSN： 1386-341X            Impact factor:   4.107


× No keyword cloud information.
  10 in total

Review 1.  Management of resistant prolactinomas.

Authors:  Agusta Olafsdottir; Janet Schlechte
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-10

2.  Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.

Authors:  B M Biller; M E Molitch; M L Vance; K B Cannistraro; K R Davis; J A Simons; J R Schoenfelder; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

3.  Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.

Authors:  Mirta Knoepfelmacher; Miriam C Gomes; Maria E Melo; Berenice B Mendonca
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

4.  Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.

Authors:  A Di Sarno; M L Landi; P Cappabianca; F Di Salle; F W Rossi; R Pivonello; C Di Somma; A Faggiano; G Lombardi; A Colao
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

5.  Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.

Authors:  L Caccavelli; F Feron; I Morange; E Rouer; R Benarous; D Dewailly; P Jaquet; C Kordon; A Enjalbert
Journal:  Neuroendocrinology       Date:  1994-09       Impact factor: 4.914

6.  Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.

Authors:  Annamaria Colao; Giovanni Vitale; Paolo Cappabianca; Francesco Briganti; Antonio Ciccarelli; Michele De Rosa; Stefano Zarrilli; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

7.  Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.

Authors:  M Filopanti; A M Barbieri; A R Angioni; A Colao; V Gasco; S Grottoli; A Peri; S Baglioni; M F Fustini; F Pigliaru; P D Monte; G Borretta; B Ambrosi; M L Jaffrain-Rea; M Gasperi; S Brogioni; S Cannavò; G Mantovani; P Beck-Peccoz; A Lania; A Spada
Journal:  Pharmacogenomics J       Date:  2008-03-11       Impact factor: 3.550

8.  Resistance to bromocriptine in prolactinomas.

Authors:  I Pellegrini; R Rasolonjanahary; G Gunz; P Bertrand; S Delivet; C P Jedynak; C Kordon; F Peillon; P Jaquet; A Enjalbert
Journal:  J Clin Endocrinol Metab       Date:  1989-09       Impact factor: 5.958

Review 9.  Pituitary tumor apoplexy: a review.

Authors:  Rita N Nawar; Dima AbdelMannan; Warren R Selman; Baha M Arafah
Journal:  J Intensive Care Med       Date:  2008 Mar-Apr       Impact factor: 3.510

Review 10.  Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.

Authors:  L A Behan; M S Draman; C Moran; T King; R K Crowley; E P O'Sullivan; D Smith; C J Thompson; A Agha
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107
  10 in total
  4 in total

1.  Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.

Authors:  M Jian; Q Du; D Zhu; Z Mao; X Wang; Y Feng; Z Xiao; H Wang; Y Zhu
Journal:  J Endocrinol Invest       Date:  2018-10-28       Impact factor: 4.256

Review 2.  Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.

Authors:  Claudia Pivonello; Roberta Patalano; Mariarosaria Negri; Rosa Pirchio; Annamaria Colao; Rosario Pivonello; Renata Simona Auriemma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-12       Impact factor: 5.555

3.  A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

Authors:  Rakesh Mishra; Subhas K Konar; Adesh Shrivastava; Pradeep Chouksey; Sumit Raj; Amit Agrawal
Journal:  Indian J Endocrinol Metab       Date:  2022-02-17

4.  The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.

Authors:  Xiong Wang; Yonggang Chen; Jinhu Wu; Shuman Wang; Aihua Wang; Yu Zhang; Kejing Zhu
Journal:  BMC Endocr Disord       Date:  2021-11-23       Impact factor: 2.763
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.